Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer
7
×
life sciences
national blog main
national top stories
san diego blog main
7
×
san diego top stories
san francisco blog main
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
fda
novartis
startups
bristol-myers squibb
cancer immunotherapy
deals
investing
ipo
merck
nivolumab
venture capital
What
new
7
×
bio
drug
roundup
companies
drugs
fda
ipo
life
science
activity
advance
advantages
approval
approvals
approved
bails
bar
biogen
biogen’s
biologic
biology
biopharmaceutical
biotechs
brand
bridgebio
brings
cancer
capital
car
clamped
club
continued
convo
covid
crop
cytokine
deeper
delays
demonstrating
Language
unset
Current search:
new
×
cancer
×
" san diego blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs